For the year ending 2025-12-31, JANX had -$378,271K decrease in cash & cash equivalents over the period. -$83,278K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -113,625 |
| Depreciation | 2,029 |
| Stock-based compensation | 40,221 |
| Accretion of discounts on investments, net | 17,574 |
| Prepaid expenses and other current assets | 827 |
| Other long-term assets | -276 |
| Accounts payable | 977 |
| Accrued expenses | 6,290 |
| Deferred revenue | 0 |
| Operating lease right-of-use assets and liabilities, net | 2 |
| Net cash used in operating activities | -82,235 |
| Purchases of property and equipment | 1,043 |
| Purchases of short-term investments | 705,222 |
| Maturities of short-term investments | 405,284 |
| Net cash used in investing activities | -300,981 |
| Proceeds from exercise of common stock options and employee stock purchase plan | 5,292 |
| Proceeds from the issuance of common stock and pre-funded common stock warrants, net of issuance costs | -347 |
| Net cash provided by financing activities | 4,945 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -378,271 |
| Cash, cash equivalents and restricted cash - beginning of year | 431,421 |
| Cash, cash equivalents and restricted cash - end of period | 53,150 |
Janux Therapeutics, Inc. (JANX)
Janux Therapeutics, Inc. (JANX)